FDA Grants Premarket Approval (PMA) for the NeuroPace® RNS® System to Treat Medically Refractory Epilepsy
The RNS(R) System has been granted premarket approval (PMA) from the FDA for the treatment of adults with partial onset seizures that have not been controlled with two or more antiepileptic drugs. The RNS System is a novel, implantable therapeutic device that delivers responsive neurostimulation, an advanced technology designed to detect abnormal electrical activity in the brain and respond by delivering imperceptible levels of electrical stimulation to normalize brain activity before an individual experiences seizures.
Business Wire press release available: http://www.businesswire.com/news/home/20131114006420/en/FDA-Grants-Premarket-Approval-PMA-NeuroPace%C2%AE-RNS%C2%AE
Post time: 12-25-2016